AGP Executive Report
Last update: 8 hours agoCardiovascular Drug Setback: Novartis and Ionis’ pelacarsen (an RNA therapy targeting Lp(a)) missed its Phase 3 goal, failing to reduce heart attacks, strokes, or death despite lowering Lp(a) levels—raising questions for the next wave of heart-protection strategies. Health Plan Network Shock: Mass General Brigham Health Plan is removing Dana-Farber from its Medicare Advantage network, leaving about 1,000 patients facing coverage changes after a 90-day transition. Mental Health Access: Vermont opened the Asha Clinic in Burlington, a specialized outpatient program focused exclusively on suicide care, led by suicide researcher Dr. Craig Bryan. Public Health & Safety: Kentucky received $213M for rural health upgrades, while a UK rabies-vaccine batch was flagged as substandard by regulators—prompting a manufacturer response about supply-chain release. Clinical Tech in Oncology: New talks highlight how AI is being used to streamline tumor boards and treatment planning, plus open-source tools for PSMA PET/CT segmentation. Weight-Loss Counterfeit Warning: UK reporting says illicit copycat retatrutide is circulating widely despite the drug not being approved for human use. Food & Pharma Compliance: India’s drug regulator seized potentially spurious rabies vaccine vials, and a US antitrust settlement has Zydus Pharmaceuticals USA paying $5.9M to resolve pricing litigation.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.